Literature DB >> 35974164

Critical appraisal of serum urate targets in the management of gout.

Lisa K Stamp1, Nicola Dalbeth2.   

Abstract

Gout management involves two broad aspects: treatment of gout flares to provide rapid symptomatic relief and long-term urate-lowering therapy to lower serum urate sufficiently to prevent gout flares from occurring. All of the major rheumatology societies recommend a target serum urate of <5 mg/dl (<0.30 mmol/l) or <6 mg/dl (<0.36 mmol/l), both of which are below the point of saturation for urate and therefore lead to monosodium urate crystal dissolution. In this Review, we describe the rationale for treat-to-target urate approach in the long-term management of gout and the current evidence and controversy around the appropriate serum urate targets.
© 2022. Springer Nature Limited.

Entities:  

Year:  2022        PMID: 35974164     DOI: 10.1038/s41584-022-00816-1

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   32.286


  53 in total

1.  Observations on certain pathological conditions of the blood and urine, in gout, rheumatism, and Bright's disease.

Authors:  A B Garrod
Journal:  Med Chir Trans       Date:  1848

Review 2.  Challenges in Implementing Treat-to-Target Strategies in Rheumatology.

Authors:  Julia A Ford; Daniel H Solomon
Journal:  Rheum Dis Clin North Am       Date:  2019-02       Impact factor: 2.670

3.  The influence of temperature on the solubility of monosodium urate.

Authors:  J N Loeb
Journal:  Arthritis Rheum       Date:  1972 Mar-Apr

4.  Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis.

Authors:  Nicola Dalbeth; Amanda Phipps-Green; Christopher Frampton; Tuhina Neogi; William J Taylor; Tony R Merriman
Journal:  Ann Rheum Dis       Date:  2018-02-20       Impact factor: 19.103

Review 5.  Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN).

Authors:  Nicola Dalbeth; Thomas Bardin; Michael Doherty; Frédéric Lioté; Pascal Richette; Kenneth G Saag; Alexander K So; Lisa K Stamp; Hyon K Choi; Robert Terkeltaub
Journal:  Nat Rev Rheumatol       Date:  2017-08-10       Impact factor: 20.543

6.  Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians.

Authors:  Amir Qaseem; Russell P Harris; Mary Ann Forciea; Thomas D Denberg; Michael J Barry; Cynthia Boyd; R. Dobbin Chow; Linda L Humphrey; Devan Kansagara; Sandeep Vijan; Timothy J Wilt
Journal:  Ann Intern Med       Date:  2016-11-01       Impact factor: 25.391

7.  Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.

Authors:  E W Campion; R J Glynn; L O DeLabry
Journal:  Am J Med       Date:  1987-03       Impact factor: 4.965

Review 8.  Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.

Authors:  Mats Dehlin; Lennart Jacobsson; Edward Roddy
Journal:  Nat Rev Rheumatol       Date:  2020-06-15       Impact factor: 20.543

Review 9.  2016 updated EULAR evidence-based recommendations for the management of gout.

Authors:  P Richette; M Doherty; E Pascual; V Barskova; F Becce; J Castañeda-Sanabria; M Coyfish; S Guillo; T L Jansen; H Janssens; F Lioté; C Mallen; G Nuki; F Perez-Ruiz; J Pimentao; L Punzi; T Pywell; A So; A K Tausche; T Uhlig; J Zavada; W Zhang; F Tubach; T Bardin
Journal:  Ann Rheum Dis       Date:  2016-07-25       Impact factor: 19.103

Review 10.  Pathophysiology of Gout.

Authors:  Ravi K Narang; Nicola Dalbeth
Journal:  Semin Nephrol       Date:  2020-11       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.